Canada - English
Canada - Français
New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0 to 25.
For a refined risk estimateof local recurrence
The Oncotype DX GPS assay is fully covered by Medicare for localized prostate cancer patients.
Nuclear-specific vs. nuclear-agnostic AR-V7 testing
Help Stage II colon cancer patients understand the power of genomics
Your Oncotype DX score can help you decide.
Oncotype DX has helped thousands of women find out.
When Dan's Colon Recurrence Score came back low, he decided against chemotherapy.
Are you looking to order the new Oncotype MAP Pan-cancer Tissue Test? Please use this form to contact Customer Service.
Delegates can fill out and submit online orders on your behalf. If you do not need to add other physicians or delegates to your account, you can skip this page.
NOTE: If you need to submit more than 5 new users, please contact Customer Service.
Learn about the test→
Have questions? We're here to help.